Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
PRISTIQ: selected primary-label renal guidance and limits
Product / population
Adult PRISTIQ extended-release tablets for major depressive disorder; swallow whole, not divided or crushed.
Renal method
Cockcroft-Gault CrCl, mL/min
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
PRISTIQ: source applicability and renal evidence limits
No supplemental post-dialysis dose. The RX mirror is not independent corroboration of the matched label.
What to reconcile: Swallow ER tablets whole; taper rather than abruptly discontinue.
DailyMed / product prescribing information · Adult PRISTIQ extended-release tablets for major depressive disorder; swallow whole, not divided or crushed.
Renal method: Cockcroft-Gault CrCl, mL/min Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
No supplemental post-dialysis dose.
Dialysis evidence: A regimen is reported in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 2.2; sections 2.1 and 2.5
Limits that apply to these rows
Read the complete source-specific limitations above and below this table. No patient dose is calculated.
Source-specific renal instructions
CrCl (mL/min)
Maximum dose
30-50
50 mg once daily
15-29 or ESRD <15
25 mg daily OR 50 mg every other day
After dialysis
No supplemental dose
Read the retained text before reformatting
At CrCl 30-50 mL/min, the maximum is 50 mg daily. At CrCl 15-29 or ESRD below 15, the maximum is 25 mg daily or 50 mg every other day. Do not give supplemental doses after dialysis. These are renal maximums, not instructions to escalate. Taper when discontinuing and retain the full antidepressant safety and interaction review.
RDM72-desvenlafaxine-label-1 · Source locator: Section 2.2; sections 2.1 and 2.5
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
